The Next Generation Tissue Biomarkers Market was valued at USD 3.02 Billion in 2024, and is projected to reach USD 5.98 Billion by 2030, rising at a CAGR of 12.74%. Key driving factors such as increasing prevalence of chronic diseases, technological advancements in biomarker detection techniques, and rising demand for personalized medicines are responsible for market growth. There is a global increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases.
Increasing technological advancements for detecting next generation tissue biomarkers boost the growth of the market. The development of high throughput screening technologies such as next-generation sequencing (NGS) has significantly enhanced the ability to analyze genetic mutations and gene expression profiles in cancer tissues. Furthermore, liquid biopsies, high throughput screening technologies, epigenetic profiling, and microRNA-based biosensors are in practice for next generation tissue biomarker detection. Collectively, these technological advancements are transforming the landscape of tissue biomarker discovery, leading to more accurate diagnostics, personalized treatment strategies, and improved patient outcomes. AI and machine learning algorithms are being incorporated into digital pathology, automating the analysis of tissue images. The growing demand for personalized medicines is another key factor responsible for market growth. These personalized medicines are increasingly leveraging next-generation tissue biomarkers to tailor treatments to individual patients.
For the detection of biomarkers, in February 2025, Alida Biosciences (AlidaBio), a company in epigenomic research tools, officially announced the full commercial launch of its EpiPlex platform. This groundbreaking platform is the first to simultaneously detect and quantify multiple RNA modifications through short-read sequencing while also providing gene expression data.
In February 2025, Biofidelity, a provider of genomic solutions, unveiled details about the launch of Enspyre, an innovative target enrichment technology with a wide range of potential applications. A groundbreaking target enrichment technology that greatly improves next-generation sequencing (NGS) efficiency by selectively eliminating background DNA.
In September 2024, Genialis, an RNA biomarker company, announced the launch of Genialis krasID, the first biomarker algorithm capable of predicting patient response and clinical benefit to KRAS inhibitors (KRASi) across different tissue histologies and mutation types. Genialis krasID can assist in guiding drug development from early preclinical stages, such as compound/MOA differentiation and selection, to clinical trials.
Another novel senescent cell targeting molecules was developed in October 2024. Illumina, Inc., a company in DNA sequencing and array-based technologies, introduced its MiSeq i100 Series of sequencing systems today, offering unmatched benchtop speed and ease of use to enhance next-generation sequencing (NGS) in laboratories.
In September 2021, Roche announced the release of the AVENIO Tumor Tissue CGP Kit. This new kit enhances the existing CGP portfolio from Roche and Foundation Medicine, enabling laboratories to conduct more extensive oncology research in-house. The introduction of this kit will greatly increase global access to genomic profiling by offering an in-house solution for those unable to access our tests through centralized laboratories, the company stated.
This product will be delivered within 1-3 business days.
Increasing technological advancements for detecting next generation tissue biomarkers boost the growth of the market. The development of high throughput screening technologies such as next-generation sequencing (NGS) has significantly enhanced the ability to analyze genetic mutations and gene expression profiles in cancer tissues. Furthermore, liquid biopsies, high throughput screening technologies, epigenetic profiling, and microRNA-based biosensors are in practice for next generation tissue biomarker detection. Collectively, these technological advancements are transforming the landscape of tissue biomarker discovery, leading to more accurate diagnostics, personalized treatment strategies, and improved patient outcomes. AI and machine learning algorithms are being incorporated into digital pathology, automating the analysis of tissue images. The growing demand for personalized medicines is another key factor responsible for market growth. These personalized medicines are increasingly leveraging next-generation tissue biomarkers to tailor treatments to individual patients.
For the detection of biomarkers, in February 2025, Alida Biosciences (AlidaBio), a company in epigenomic research tools, officially announced the full commercial launch of its EpiPlex platform. This groundbreaking platform is the first to simultaneously detect and quantify multiple RNA modifications through short-read sequencing while also providing gene expression data.
In February 2025, Biofidelity, a provider of genomic solutions, unveiled details about the launch of Enspyre, an innovative target enrichment technology with a wide range of potential applications. A groundbreaking target enrichment technology that greatly improves next-generation sequencing (NGS) efficiency by selectively eliminating background DNA.
In September 2024, Genialis, an RNA biomarker company, announced the launch of Genialis krasID, the first biomarker algorithm capable of predicting patient response and clinical benefit to KRAS inhibitors (KRASi) across different tissue histologies and mutation types. Genialis krasID can assist in guiding drug development from early preclinical stages, such as compound/MOA differentiation and selection, to clinical trials.
Another novel senescent cell targeting molecules was developed in October 2024. Illumina, Inc., a company in DNA sequencing and array-based technologies, introduced its MiSeq i100 Series of sequencing systems today, offering unmatched benchtop speed and ease of use to enhance next-generation sequencing (NGS) in laboratories.
In September 2021, Roche announced the release of the AVENIO Tumor Tissue CGP Kit. This new kit enhances the existing CGP portfolio from Roche and Foundation Medicine, enabling laboratories to conduct more extensive oncology research in-house. The introduction of this kit will greatly increase global access to genomic profiling by offering an in-house solution for those unable to access our tests through centralized laboratories, the company stated.
Next Generation Tissue Biomarkers Market Report Highlights
- Based on product, reagents and assays accounted for the largest revenue share of 55.97% in 2024. This segment is expected to see rapid expansion due to its broad applicability in biopharmaceutical research. A key driving factor is the growing need for early disease detection and diagnostics, which has resulted in high demand for accurate, reliable, and rapid diagnostics, contributing to market growth.
- Based on type, the genomic biomarker segment dominated the market in 2024 owing to the rising demand for innovative therapies, growing competition for early disease detection, and significant R&D investments. Metabolomic biomarkers are expected to grow fastest over the forecast period. Metabolomic biomarkers refer to specific metabolic changes or substances in the body that can be measured and used to identify disease states, predict disease risk, and monitor responses to treatments.
- Based on technology, the next generation sequencing segment dominated the market with the largest revenue share in 2024. Next Generation Sequencing (NGS) refers to the huge DNA sequencing methods that aid in genomic discovery. The spatial genomics biology segment is anticipated to witness growth at the fastest CAGR from 2024 to 2030. The advancements in genome editing tools, such as the CRISPR/Cas9 system, have facilitated spatial genomics biology adoption, driving market growth.
- Based on application, the oncology segment dominated the market with the largest revenue share in 2024. The growing demand for precision medicine drives the segment growth and targeted cancer therapies. Companion diagnostics are expected to grow fastest over the forecast period. The companion diagnostics market is experiencing significant product expansion, with new assays being developed for various cancer types, autoimmune diseases, and neurological disorders.
- Based on end use, the hospitals & reference labs segment dominated the market with the largest revenue share in 2024. Hospitals and reference labs are rapidly adopting next generation tissue biomarkers to enhance efficiency, accuracy, and accessibility. Contract research organizations are projected to grow significantly during the forecast period.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Next Generation Tissue Biomarkers Market Variables, Trends & Scope
Chapter 4. Next Generation Tissue Biomarkers Market: Product Estimates & Trend Analysis
Chapter 5. Next Generation Tissue Biomarkers Market: Type Estimates & Trend Analysis
Chapter 6. Next Generation Tissue Biomarkers Market: Technology Estimates & Trend Analysis
Chapter 7. Next Generation Tissue Biomarkers Market: Application Estimates & Trend Analysis
Chapter 8. Next Generation Tissue Biomarkers Market: End Use Estimates & Trend Analysis
Chapter 9. Next Generation Tissue Biomarkers Market: Regional Estimates & Trend Analysis
Chapter 10. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Next Generation Tissue Biomarkers market report include:- Roche Diagnostics/Ventana Medical Systems
- Agilent Technologies/Dako
- Leica Biosystems (Danaher Corporation)
- Thermo Fisher Scientific
- Illumina
- Qiagen
- NeoGenomics.
- NanoString Technologies
- Akoya Biosciences
- Bio-Techne / ACD
- Guardant Health
